Monopar Therapeutics (MNPR) investor relations material

Executive summary

• Clinical-stage biopharma focused on ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology, with multiple programs in late preclinical and clinical phases.

• Initiated rolling NDA submission for ALXN1840 for Wilson disease, with completion expected in the coming months; FDA granted Rare Pediatric Disease designation, potentially enabling a Priority Review Voucher upon approval.

• Presented new clinical data showing significant neurologic and liver benefits for ALXN1840 in Wilson disease patients at major medical conferences.

• Strengthened commercial leadership team in preparation for potential product launch.

• No revenue generated to date; company remains pre-commercial and expects continued operating losses as it advances its pipeline.

Financial highlights

• Cash, cash equivalents, and investments totaled $134.3 million as of June 30, 2026, expected to fund operations through at least December 31, 2027.

• Net loss for Q2 2026 was $5.3 million ($0.62 per share), compared to $2.5 million ($0.35 per share) in Q2 2025; net loss for the first half of 2026 was $9.2 million, up from $5.1 million in the prior year period.

• Research and development expenses rose to $4.8 million in Q2 2026 (up $3.04 million year-over-year), driven by higher contractor, consulting, and personnel costs.

• General and administrative expenses increased to $1.9 million in Q2 2026 (up $0.37 million year-over-year), mainly due to higher personnel and consulting expenses.

• Interest income increased to $1.3 million in Q2 2026, reflecting higher balances from a 2025 capital raise.

Outlook and guidance

• Current funds are expected to support operations, including NDA submission for ALXN1840 and ongoing clinical trials, through at least the end of 2027.

• Anticipates increased expenses for pre-commercial and potential commercialization activities for ALXN1840, as well as continued investment in radiopharmaceutical pipeline.

• Anticipates completing NDA submission for ALXN1840 within the next few months.

• Future funding needs will depend on clinical progress, regulatory outcomes, and potential commercialization.